Compare Incyte Corporation (INCY) vs Realty Income Corp (O) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Realty Income Corp — how do they compare? Incyte Corporation trades at $112.77 (market cap $22.85B), while Realty Income Corp trades at $54.25 (market cap $51.26B). The key difference: Realty Income Corp is far larger — about 2.2× Incyte Corporation's market cap, and Realty Income Corp pays a 6.01% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Realty Income Corp for 127 Days on average.
| INCY | O | |
|---|---|---|
Market Cap | $22.85B | $51.26B |
Volume | 1,927,029 | 12,300,266 |
Sector | Health | Real Estate |
52-Week High | $129.93 | $67.56 |
52-Week Low | $83.80 | $53.35 |
Typical Hold Time | 33 Days | 127 Days |
Enterprise Value | $18.35B | $81.88B |
Dividend Yield | — | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $112.79, down 0.57% on the day, with a bearish technical signal despite recent earnings beats. The company shows strong fundamentals with 2025 revenue of $5.14B and net income of $1.29B, yielding robust profit margins of 92.62% gross and 27.71% net. Recent FDA approval for Atebrioz and pipeline expansion beyond JAKAFI highlight growth initiatives. Valuation metrics appear reasonable with P/E of 14.36 and P/S of 3.98, below sector averages in some cases.
The outlook remains positive with analyst consensus price target of $132.43 implying 17% upside, though near-term pressure exists from Q3 2026 expected EPS loss. Key risks include JAKAFI patent expiration post-2029 and execution on $4B sales target. Institutional sentiment leans bullish with 52% buy ratings, supporting the growth transition story despite technical headwinds.
Realty Income (O) trades at $54.18, up 1.56% today, but remains in a bearish technical trend with recent earnings misses and a high P/E of 39.54. Revenue grew to $5.75B in 2025, with a net income margin of 21.23%, but rising debt levels and negative cash flow projections for 2026 pose concerns. Analyst sentiment is mixed, with a consensus price target of $64.80, though technical indicators signal caution.
The stock offers a defensive dividend play with consistent payouts, but faces headwinds from rising interest rates and elevated valuation. Upside depends on earnings recovery and debt management, while risks include further technical weakness and macroeconomic pressure on REITs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Realty Income Corp
Realty Income owns roughly 11,400 properties, most of which are freestanding, single-tenant, triple-net-leased retail properties. Its properties are located in 49 states and Puerto Rico and are leased to 250 tenants from 47 industries. Recent acquisitions have added industrial, office, manufacturing, and distribution properties, which make up roughly 17% of revenue.
Read more on O →
